Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

Last updated: March 25, 2025
Sponsor: Nationwide Children's Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

Responsive Management Intervention

Percutaneous Patent Ductus Arteriosus Closure (PPC)

Echocardiogram, cardiac

Clinical Study ID

NCT05547165
00002501
UG3HL161338
  • Ages 7-32
  • All Genders

Study Summary

Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory system of the baby, but is expected to close at full term birth. If the opening is tiny, the condition can be self-limiting. If not, medications/surgery are options for treatment.

There are two ways to treat patent ductus arteriosus - one is through closure of the opening with an FDA approved device called PICCOLO, the other is through supportive management (medications). No randomized controlled trials have been done previously to see if one of better than the other. Through our PIVOTAL study, the investigators aim to determine is one is indeed better than the other - if it is found that the percutaneous closure with PICCOLO is better, then it would immediately lead to a new standard of care. If not, then the investigators avoid an invasive costly procedure going forward.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. EPIs born between 22-weeks+0 days (220/7 wks) and 27-weeks+6 days (276/7 wks)gestation, inclusive

  2. Admitted to a study NICU

  3. Birth weight ≥700-grams

  4. Mechanically ventilated at time of consent and randomization

  5. HSPDA ("PDA Score" ≥6) noted on echocardiogram (ECHO)

  6. Randomization is able to be performed within 5 days of the qualifying ECHO and wheninfant is 7-32 days postnatal

Exclusion

Exclusion Criteria:

Clinical Exclusion Criteria

  1. Life-threatening congenital defects (including congenital heart disease such asaortic coarctation or pulmonary artery stenosis). PDA and small atrial/ventricularseptal defects are permitted;

  2. Congenital lung abnormalities, (e.g. restrictive lung disease);

  3. Pharyngeal or airway anomalies (tracheal stenosis, choanal atresia);

  4. Treatment for acute abdominal process (e.g., necrotizing enterocolitis);

  5. Infants with planned surgery;

  6. Active infection requiring treatment;

  7. Chromosomal defects (e.g., Trisomy 18);

  8. Neuromuscular disorders;

  9. Infants whose parents have chosen to allow natural death (do not resuscitate order)or for whom limitation of intensive care treatment is being considered (e.g. severeintraventricular hemorrhage)

  10. Physician deems that the infant would not be a Percutaneous PDA Closure candidatedue to clinical instability; however, if the infant's clinical status improvesbefore 30-days postnatal and all inclusion criteria are still met, then the infantmay be enrolled.

ECHO-based Exclusion Criteria

  1. Pulmonary hypertension (defined by ductal right to left shunting for >33% of thecardiac cycle) in which early PDA closure may increase right ventricular afterloadand compromise pulmonary and systemic blood flow;

  2. Evidence of cardiac thrombus that might interfere with device placement;

  3. PDA diameter larger than 4 mm at the narrowest portion (consistent with FDA-approvedinstructions for Piccolo™ device use).

  4. PDA length smaller than 3 mm (consistent with FDA-approved instructions for Piccolo™device use).

  5. PDA that does not meet inclusion requirements ("PDA Score" <6).* * If a potentialparticipant is found to have a PDA meeting eligibility requirements on a subsequentECHO during the required period of 7 - 30 postnatal days of age, they may then bedeclared eligible to participate and enrolled, provided all other inclusion criteriaare met and exclusion criteria are not met.

Other Exclusion Criteria

  1. Parents or legal guardian do not speak English or Spanish

Study Design

Total Participants: 240
Treatment Group(s): 3
Primary Treatment: Responsive Management Intervention
Phase:
Study Start date:
February 21, 2023
Estimated Completion Date:
February 28, 2026

Connect with a study center

  • University of Alabama

    Birmingham, Alabama 35294
    United States

    Active - Recruiting

  • Arkansas Children's Hospital

    Little Rock, Arkansas 72202
    United States

    Active - Recruiting

  • Cedars-Sinai Medical Center

    Los Angeles, California 90048
    United States

    Active - Recruiting

  • Children's Hospital Los Angeles

    Los Angeles, California 90027
    United States

    Site Not Available

  • Lucille Packard Children's Hospital at Stanford

    Palo Alto, California 94304
    United States

    Site Not Available

  • UC Davis Children's Hospital

    Sacramento, California 95817
    United States

    Active - Recruiting

  • Children's Hospital Colorado

    Aurora, Colorado 80045
    United States

    Site Not Available

  • Joe DiMaggio Children's Hospital

    Hollywood, Florida 33021
    United States

    Active - Recruiting

  • Arnold Palmer Hospital for Children

    Orlando, Florida 32806
    United States

    Site Not Available

  • Orlando Health

    Orlando, Florida 32806
    United States

    Active - Recruiting

  • Ann and Robert H. Lurie Children's Hospital

    Chicago, Illinois 60611
    United States

    Active - Recruiting

  • Boston Children's Hospital

    Boston, Massachusetts 02115
    United States

    Active - Recruiting

  • C.S. Mott Children's Hospital

    Ann Arbor, Michigan 48109
    United States

    Site Not Available

  • M Health Fairview University of Minnesota Masonic Children's Hospital

    Minneapolis, Minnesota 55455
    United States

    Site Not Available

  • University of Minnesota, Masonic Children's Hospital

    Minneapolis, Minnesota 55455
    United States

    Site Not Available

  • St. Louis Children's Hospital

    Saint Louis, Missouri 63110
    United States

    Active - Recruiting

  • Morgan Stanley Children's Hospital of New York-Presbyterian

    New York, New York 10032
    United States

    Site Not Available

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio 45229
    United States

    Site Not Available

  • Nationwide Children's Hospital

    Columbus, Ohio 43205
    United States

    Active - Recruiting

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania 19104
    United States

    Site Not Available

  • Le Bonheur Children's Medical Center

    Memphis, Tennessee 38103
    United States

    Active - Recruiting

  • Monroe Carell Jr. Children's Hospital at Vanderbilt

    Nashville, Tennessee 37232
    United States

    Site Not Available

  • Medical City Children's Dallas

    Dallas, Texas 75230
    United States

    Active - Recruiting

  • Medical City Children's Hospital

    Dallas, Texas 75230
    United States

    Site Not Available

  • UT Southwestern Children's Medical Center of Dallas

    Dallas, Texas 75235
    United States

    Active - Recruiting

  • Texas Children's

    Houston, Texas 77030
    United States

    Active - Recruiting

  • Seattle Children's

    Seattle, Washington 98105
    United States

    Active - Recruiting

  • Children's Wisconsin

    Milwaukee, Wisconsin 53226
    United States

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.